Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: 3 times a day..?

"Maybe the benefit is good and maybe it's bad, but to me it allows too much room for obviscation, non transparency, broadened insider advantage, and PTSC stock minipulation."

We have to get away from this thinking, that PRs are only directed to influence the shareprice. The main targets of today's and the '336-recert-news were not us or new investors - it was written mainly for both groups of the infringing companies:

The one group, which was already in negotiation talks, but stopped it to await the USPTO outcome. My guess is, these companies get a little financial advantage over the other group, because they were at least open for negotiations.

The other group are those companies, who were refusing to talk with TPL.

The PR from today confirms my assumption, because the word "re-engaging" tells exactly, what I said after the '336-news: The negotiation talks must have come to a halt with most of the companies in the last two years, because they wanted to wait if the patents would hold.

And for the other group a bundling of three licensees in one PR says it all:

"YOU ARE TOO LATE NOW - AND YOU HAVE TO PAY BIG."

So IMHO today's PR is perfect mirroring the needs of the TPL license guys all over the world. We'll see "real shareprice" news in the future, but for the next time I guess the main goal of PR-news is to support the license activities.

GLTY

Share
New Message
Please login to post a reply